

Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) Publication number:

**0 386 757 B1**

(12)

## EUROPEAN PATENT SPECIFICATION

(45) Date of publication of patent specification: **07.12.94** (51) Int. Cl.<sup>5</sup>: **C08G 79/04, A61K 47/48**

(21) Application number: **90104441.2**

(22) Date of filing: **08.03.90**

(54) **Biodegradable poly(phosphoesters).**

(30) Priority: **09.03.89 US 321360**

(43) Date of publication of application:  
**12.09.90 Bulletin 90/37**

(45) Publication of the grant of the patent:  
**07.12.94 Bulletin 94/49**

(84) Designated Contracting States:  
**AT BE CH DE DK ES FR GB GR IT LI LU NL SE**

(56) References cited:  
**GB-A- 753 319**  
**GB-A- 757 800**  
**US-A- 2 964 552**

**DIE MAKROMOLEKULARE CHEMIE**, vol. 190,  
no. 9, September 1989, pages 2329-2338, Bas-  
sel, DE; J.-C. BROSSE et al.: "Fixation  
d'amines pharmacologiquement activessur  
les polyphosphonates, 1"

**DIE MAKROMOLEKULARE CHEMIE**, vol. 190,  
no. 9, September 1989, pages 2339-2345, Bas-  
sel, DE; J.-C. BROSSE et al.: "Fixation of  
pharmacologically active amines on-  
polyphosphonates, 2"

(73) Proprietor: **THE JOHNS HOPKINS UNIVERSITY  
SCHOOL OF MEDICINE (a Maryland corpora-  
tion)**  
**720 Rutland Avenue**  
**Baltimore, Maryland (US)**

(72) Inventor: **Leong, Kam W.**  
**10242 Breconshire Road**  
**Ellicott City, Maryland 21043 (US)**

(74) Representative: **VOSSIUS & PARTNER**  
**Postfach 86 07 67**  
**D-81634 München (DE)**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

**Description**

The present invention relates to poly(phosphate esters) and poly(phosphonate esters), and methods of using these polymers.

5 Many polymeric materials have been used as components of devices for diagnosis or therapy, and they have made a significant impact on the clinical success of implant technology. These materials have been used as, for example, orthopedic devices, ventricular shunts, drug-carriers, contact lens', heart valves, sutures, and burn dressings. These polymers can be non-biodegradable or biodegradable.

In traditional drug delivery, it has long been recognized that tablets, capsules, and injections may not be 10 the best mode of administration. These conventional routes often involve frequent and repeated doses, resulting in a "peak and valley" pattern of therapeutic agent concentration. Since each therapeutic agent has a therapeutic range above which it is toxic and below which it is ineffective, a fluctuating therapeutic agent concentration may cause alternating periods of ineffectiveness and toxicity. For this reason, controlled release provides a way of maintaining the therapeutic agent level within the desired therapeutic range for 15 the duration of treatment. Using a polymeric carrier is one effective means to deliver the therapeutic agent locally and in a controlled fashion (Langer, et al., Rev. Macro. Chem. Phys., C23(1), 61, 1983). As a result of less total drug required, systemic side effects can be minimized.

20 Polymers have been used as carriers of the therapeutic agents to effect a localized and sustained release (Controlled Drug Delivery, Vol. I and II, Bruck, S.D., (ed.), CRC Press, Boca Raton, FL, 1983; Novel Drug Delivery Systems, Chien, Y.W., Marcel Dekker, New York, 1982). These therapeutic agent delivery systems simulate infusion and offer the potential of enhanced therapeutic efficacy and reduced systemic toxicity.

25 For a non-biodegradable matrix, the steps leading to release of the therapeutic agent are water diffusion into the matrix, dissolution of the therapeutic agent, and out-diffusion of the therapeutic agent through the channels of the matrix. As a consequence, the mean residence time of the therapeutic agent existing in the soluble state is longer for a non-biodegradable matrix than for a biodegradable matrix where a long passage 30 through the channels is no longer required. Since many pharmaceuticals have short half-lives it is likely that the therapeutic agent is decomposed or inactivated inside the non-biodegradable matrix before it can be released. This issue is particularly significant for many bio-macromolecules and smaller polypeptides, since these molecules are generally unstable in buffer and have low permeability through polymers. In fact, in a non-biodegradable matrix, many bio-macromolecules will aggregate and precipitate, clogging the channels necessary for diffusion out of the carrier matrix. This problem is largely alleviated by using a biodegradable matrix which allows controlled release of the therapeutic agent.

35 Biodegradable polymers differ from non-biodegradable polymers in that they are consumed or biodegraded during therapy. This usually involves breakdown of the polymer to its monomeric subunits, which should be biocompatible with the surrounding tissue. The life of a biodegradable polymer in vivo depends on its molecular weight and degree of cross-linking; the greater the molecular weight and degree of crosslinking, the longer the life. The most highly investigated biodegradable polymers are polylactic acid (PLA), polyglycolic acid (PGA), copolymers of PLA and PGA, polyamides, and copolymers of polyamides 40 and polyesters. PLA, sometimes referred to as polylactide, undergoes hydrolytic de-esterification to lactic acid, a normal product of muscle metabolism. PGA is chemically related to PLA and is commonly used for absorbable surgical sutures, as is PLA/PGA copolymer. However, the use of PGA in sustained-release implants has been limited due to its low solubility in common solvents and subsequent difficulty in fabrication of devices.

45 An advantage of a biodegradable material is the elimination of the need for surgical removal after it has fulfilled its mission. The appeal of such a material is more than simply for convenience. From a technical standpoint, a material which biodegrades gradually and is excreted over time can offer many unique advantages.

50 A biodegradable therapeutic agent delivery system has several additional advantages: 1) the therapeutic agent release rate is amenable to control through variation of the matrix composition; 2) implantation can be done at sites difficult or impossible for retrieval; 3) delivery of unstable therapeutic agents is more practical. This last point is of particular importance in light of the advances in molecular biology and genetic engineering which have lead to the commercial availability of many potent bio-macromolecules. The short in vivo half-lives and low GI tract absorption of these polypeptides render them totally unsuitable for 55 conventional oral or intravenous administration. Also, because these substances are often unstable in buffer, such polypeptides cannot be effectively delivered by pumping devices.

In its simplest form, a biodegradable therapeutic agent delivery system consist of a dispersion of the drug solutes in a polymer matrix. The therapeutic agent is released as the polymeric matrix decomposes, or

5 biodegrades into soluble products which are excreted from the body. Several classes of synthetic polymers, including polyesters (Pitt, et al., in Controlled Release of Bioactive Materials, R. Baker, Ed., Academic Press, New York, 1980); polyamides (Sidman, et al., Journal of Membrane Science, 7:227, 1979); polyurethanes (Maser, et al., Journal of Polymer Science, Polymer Symposium, 66:259, 1979); polyorthoesters (Heller, et al., Polymer Engineering Science, 21:727, 1981); and polyanhydrides (Leong, et al., Biomaterials, 7:364, 1986) have been studied for this purpose.

10 By far most research has been done on the polyesters of PLA and PLA/PGA. Undoubtedly, this is a consequence of convenience and safety considerations. These polymers are readily available, as they have been used as biodegradable sutures, and they decompose into non-toxic lactic and glycolic acids. However, a major problem with these polymers is that it is often difficult to control and predict their degradation.

15 Polyorthoesters and polyanhydrides have been specifically designed for controlled release purposes. While these polymers are promising, they also have significant drawbacks. For example, polyorthoesters biodegrade in a desirable manner only if additives are included in the matrix. By taking advantage of the pH dependence of the rate of orthoester cleavage, preferential hydrolysis at the surface is achieved by either 20 the addition of basic substances to suppress degradation in bulk, or the incorporation of acidic catalysts to promote surface degradation. Unfortunately, these additives often lead to unnecessary complications in terms of release behavior and biocompatibility.

25 The polyanhydrides, on the other hand, are unstable even in the solid state. In addition, the poor solubility of the hydrophobic polyanhydrides also render characterization and fabrication difficult. Hence there exists the need for new biodegradable polymers.

The biodegradable matrix of the invention also finds broad utility as a transient prosthetic support in orthopedic applications. For centuries, physicians have attempted to repair and replace various components of the skeletal system. These attempts have utilized various kinds of materials including bone, ivory, collagen, wood, metals, alloys, ceramics, glasses, corals, carbons, polymers, and composites of materials 30 as bone prostheses.

Ideally, the bone prosthesis should be a material that is biologically inert, readily available, easily adaptable to the site in terms of shape and size, and replaceable by the host bone. Replacement of the prosthesis by the host bone necessitates that the substitute be biodegradable.

35 The different elastic moduli of the prior art prosthetic implants versus that of bone often causes cortical bone to atrophy. The theoretical advantage of gradual load transfer from the bone plate to the bone and the elimination of the need for surgical removal after the healing of a fracture would make an absorbable osteosynthesis material extremely useful. As a temporary support in a load-bearing area of an articular joint, a resorbable porous material also has the advantage of preventing further destruction of cartilage defects and promoting bone and cartilage-forming cells. Hence, a need exists for a biodegradable prosthesis of sufficient post-implantation strength and rigidity to provide structural support.

40 The present invention pertains to a biodegradable composition useful as a structural prosthesis and a therapeutic agent delivery vehicle and methods for its manufacture and use. The composition comprises a biocompatible poly(phosphate ester) or poly(phosphonate ester) matrix, prepared in preselected dimensions and configurations, which predictably degrades in vivo into non-toxic residues. The method of using the composition as an implant and prosthesis comprises the step of introducing a specifically configured composition into an individual in vivo at a predetermined site.


45 Although it is preferred that the polymers of the invention be biodegradable and in matrix form, these characteristics are not essential for the polymers.

The composition of the invention, through its transient in vivo presence, provides a matrix which persists for a period of time sufficient to achieve a medical effect, essentially lacks host toxicity upon degradation, provides mechanical strength, and is readily fabricated.

FIGURE 1(a) shows the in vitro release of different pendant R groups when attached to a poly(2-oxo-1,3,2-dioxaphosphite) backbone matrix. FIGURE 1(b) compares the release of nitrophenol and aniline from a composition matrix system and a pendant system.

50 FIGURE 2 compares the degradation rates of various poly(phosphate esters) having the formula

55



wherein X for each bisphenol A (BPA) polymer matrix represented therein is as follows:




10 FIGURE 3 shows the release rates of non-pendant cortisone from various poly(phosphate ester) matrices.

FIGURE 4 illustrates the release rates of four different drugs form the same BPA polymer matrix.

The present invention is directed to compositions useful as prostheses and as therapeutic agent delivery vehicles. These compositions comprise a biodegradable, biocompatible class of poly(phosphate esters) and poly(phosphonate esters). The polymers are biodegradable because of the hydrolyzable phosphate ester, or P(O)-O-C bond, in the backbone. With the phosphate ester linkage, the polymers can be classified as polyphosphates, polyphosphonates, or polyamidophosphates, depending on the structure of the pendant groups.

The compositions comprise a biodegradable poly-phosphate or polyphosphonate matrix which comprise 20 units of the general formula:




wherein n is from 10 to 10<sup>5</sup>.


The R' group can be a therapeutic agent or, alternatively, can be selected from:

-(CH<sub>2</sub>)<sub>a</sub>-, -(CH<sub>2</sub>CH<sub>2</sub>O)<sub>b</sub>-,


30




35



40





45



50 wherein R<sub>1</sub> is independently alkyl, halogen, nitro, hydroxyl, amino, carboxyl, or alkoxy, R<sub>2</sub> is oxygen or N-CH<sub>3</sub>, and a ranges from 2 to 6, b ranges from 10 to 100, d ranges from 2 to 16, f ranges from 1 to 6, and m ranges from 1 to 2.

The R group can be a therapeutic agent or, alternatively when R' is a therapeutic agent, R can be selected from:


55                    -NH-R<sub>1</sub>, -S-R<sub>1</sub>,

5       $-\text{OC}_p\text{H}_{2p+1}, -\text{C}_p\text{H}_{2p+1},$ 

10


 $-\text{H}, -\text{Cl}, -\text{O---R}_3$ wherein  $\text{R}_1$  is alkyl, halogen, nitro, hydroxyl, amino, carboxyl, alkoxy, or combinations thereof,  
 $\text{R}_3$  is

15



20    or

25




and p ranges from 1 to 16


30    It is also possible for R and R' to be the same or different therapeutic agent.

The term "alkyl" as used herein, either alone or as a part of another group (e.g., alkoxy), means  $\text{C}_{1-16}$ , preferably  $\text{C}_{1-10}$ -alkyl.35    The common synthesis and chemical structures of polyphosphates and polyphosphonates are shown in Eqs. 1 and 2, respectively. On hydrolysis the polymers decompose into monomeric phosphates and diols (Eq. 3). However, because of the hydrolytic instability of the phosphorous ester bond, there have not been any commercial applications for these polymers (Sandler, et al., in *Polymer Synthesis*, Vol. 1, Chap. 13, Academic Press, New York, 1974). It is this instability, however, which the present inventor discovered, renders these polymers attractive for achieving a medical effect for both transient structural prosthesis and therapeutic agent controlled release applications.

40



45



50



55    In comparing the hydrolytic reactivity of different carbonyl bonds, the phosphorous ester is comparable to, or slightly more reactive than, the carboxylic ester. Thus, this water labile linkage provides the basis for a versatile delivery system.

A wide range of degradation rates can be obtained by adjusting the hydrophobicities of the backbones of the polymers and yet the biodegradability is assured. This can be achieved by varying the functional groups R or R'. The combination of a hydrophobic backbone and a hydrophilic linkage also leads to heterogeneous degradation as cleavage is encouraged, but water penetration is resisted.

5 The polyphosphates and polyphosphonates of the invention show favorable mechanical strength because of the high molecular weights obtainable. Average molecular weight of up to 600,000 has been obtained by an interfacial polymerization (Sandler, et al., ibid). This high molecular weight leads to transparency, and film and fiber properties. It has also been observed that the P-O-C group provides a plasticizing effect, which lowers the glass transition temperature of the polymer and confers solubility in  
10 organic solvents. Both effects are desirable for fabrication of the composition.

The term "therapeutic agent" as used herein for the compositions of the invention includes, without limitation, drugs, radioisotopes, immunomodulators, and lectins. Similar substances are within the skill of the art. The term "individual" includes human as well as non-human animals.

15 The drugs with which can be incorporated in the compositions of the invention include non-proteinaceous as well as proteinaceous drugs. The term "non-proteinaceous drugs" encompasses compounds which are classically referred to as drugs such as, for example, mitomycin C, daunorubicin, vinblastine, AZT, and hormones. Similar substances are within the skill of the art.

20 The proteinaceous drugs which can be incorporated in the compositions of the invention include immunomodulators and other biological response modifiers. The term "biological response modifiers" is meant to encompass substances which are involved in modifying the immune response in such manner as to enhance the particular desired therapeutic effect, for example, the destruction of the tumor cells. Examples of immune response modifiers include such compounds as lymphokines. Examples of lymphokines include tumor necrosis factor, the interleukins, lymphotoxin, macrophage activating factor, migration inhibition factor, colony stimulating factor and the interferons. Interferons which can be incorporated into  
25 the compositions of the invention include alpha-interferon, beta-interferon, and gamma-interferon and their subtypes. In addition, peptide or polysaccharide fragments derived from these proteinaceous drugs, or independently, can also be incorporated. Also, encompassed by the term "biological response modifiers" are substances generally referred to as vaccines wherein a foreign substance, usually a pathogenic organism or some fraction thereof, is used to modify the host immune response with respect to the  
30 pathogen to which the vaccine relates. Those of skill in the art will know, or can readily ascertain, other substances which can act as proteinaceous drugs.

In using radioisotopes certain isotopes may be more preferable than others depending on such factors, for example, as tumor distribution and mass as well as isotope stability and emission. Depending on the type of malignancy present some emitters may be preferable to others. In general, alpha and beta particle-emitting radioisotopes are preferred in immunotherapy. For example, if an animal has solid tumor foci a high energy beta emitter capable of penetrating several millimeters of tissue, such as <sup>90</sup>Y, may be preferable. On the other hand, if the malignancy consists of single target cells, as in the case of leukemia, a short range, high energy alpha emitter such as <sup>212</sup>Bi may be preferred. Examples of radioisotopes which can be incorporated in the compositions of the invention for therapeutic purposes are <sup>125</sup>I, <sup>131</sup>I, <sup>90</sup>Y, <sup>67</sup>Cu,  
40 <sup>212</sup>Bi, <sup>211</sup>At, <sup>212</sup>Pb, <sup>47</sup>Sc, <sup>109</sup>Pd and <sup>188</sup>Re. Other radioisotopes which can be incorporated into the compositions of the invention are within the skill in the art.

Lectins are proteins, usually isolated from plant material, which bind to specific sugar moieties. Many lectins are also able to agglutinate cells and stimulate lymphocytes. Other therapeutic agents which can be used therapeutically with the biodegradable compositions of the invention are known, or can be easily ascertained, by those of ordinary skill in the art.


45 The term "therapeutically effective" as it pertains to the compositions of the invention means that the therapeutic agent is present at concentrations sufficient to achieve a particular medical effect for which the therapeutic agent is intended. Examples, without limitation, of desirable medical effects which can be attained are chemotherapy, antibiotic therapy, birth control, and regulation of metabolism.

50 "Therapeutic-agent bearing" as it applies to the compositions of the invention denotes that the composition incorporates a therapeutic agent which is 1) not bound to the polymeric matrix, or 2) bound within the polymeric backbone matrix, or 3) pendants bound to the polymeric matrix, or 4) bound within the polymeric backbone matrix and pendants bound to the polymeric matrix. When the therapeutic agent is not bound to the matrix, then it is merely physically dispersed with the polymer matrix. When the therapeutic agent is bound within the matrix it is part of the poly(phosphate ester) backbone (R'). When the therapeutic agent is pendants attached it is chemically linked through, for example, by ionic or covalent bonding, to the side chain (R) of the matrix polymer. In the first two instances the therapeutic agent is released as the matrix biodegrades. The drug can also be released by diffusion through the polymeric matrix. In the  
55

pendant system, the drug is released as the polymer-drug bond is cleaved at the bodily tissue.

A combination of more than one therapeutic agent can be incorporated into the compositions of the invention. Such multiple incorporation can be done, for example, 1) by substituting a first therapeutic agent into the backbone matrix ( $R'$ ) and a second therapeutic agent by pendant attachment ( $R$ ), 2) by providing mixtures of different poly(phosphate esters) which have different agents substituted in the backbone matrix ( $R'$ ) or at their pendant positions ( $R$ ), 3) by using mixtures of unbound therapeutic agents with the poly(phosphate ester) which is then formed into the composition, 4) by use of a copolymer with the general structure

10



wherein m or n can be from about 1 to about 99% of the polymer, or 5) by combinations of the above.

15 The concentration of therapeutic agent in the composition will vary with the nature of the agent and its physiological role and desired therapeutic effect. Thus, for example, the concentration of a hormone used in providing birth control as a therapeutic effect will likely be different from the concentration of an anti-tumor drug in which the therapeutic effect is to ameliorate a cell-proliferative disease. In any event, the desired concentration in a particular instance for a particular therapeutic agent is readily ascertainable by one of skill in the art.

20 The therapeutic agent loading level for a composition of the invention can vary, for example, on whether the therapeutic agent is bound to the poly(phosphate ester) backbone polymer matrix. For those compositions in which the therapeutic agent is not bound to the backbone matrix, in which the agent is physically disposed with the poly(phosphate ester), the concentration of agent will typically not exceed 50 wt %. For 25 compositions in which the therapeutic agent is bound within the polymeric backbone matrix, or pendants bound to the polymeric matrix, the drug loading level is up to the stoichiometric ratio of agent per monomeric unit.

30 The term "transient structural prosthesis" when used to describe the compositions of the invention means a prosthesis which is biodegradable with time and provides a structural function in the individual such as, for example, as a vascular graft, suture and bone plate.

35 A poly(phosphate ester) and/or poly(phosphonate ester) composition of the invention can function simultaneously both as a transient structural prosthesis and as a therapeutic agent-bearing composition. An example of this would be a suture bearing a therapeutic agent such as, for example, an antibiotic, or, alternatively, a bone plate incorporating a growth factor.



40 A novel advantage of the polymers of the invention is the availability of functional side groups which allow the chemical linkage of therapeutic agents to the polymers. For example, drugs with carboxyl groups can be coupled to the phosphorous atom via an ester bond, which is hydrolyzable (Eq. 4). The rate of therapeutic agent release will then be dependent on the hydrolytic cleavage of the polymer therapeutic agent conjugate. This pendant delivery system has the advantage of attaining a high drug loading level.

45 Therapeutic agents which exist in the liquid state can also be accommodated.

Alternatively, therapeutic agents containing two hydroxyl groups can be directly incorporated into the backbone of the polymers (Eq. 5). For instance, steroids such as estradiol can be reacted with dichlorophosphates to form the polymer. Other therapeutic agents can also be derivatized for incorporation into the backbone. For instance, a drug with two amino groups can be reacted with the carboxyl group of a hydroxyl carboxylic acid. The hydroxyl groups can then be used to form the poly(phosphate ester) or poly(phosphonate ester). A sustained delivery is then effected by hydrolysis of the polymeric prodrug.

50

55



The poly(phosphate esters) and poly(phosphonate esters) of the invention can be synthesized using such polymerization methods as bulk polymerization, interfacial polymerization, solution polymerization, and ring opening polymerization (Odian, G., *Principles of Polymerization*, 2nd ed., John Wiley & Sons, New York, 1981). Using any of these methods, a variety of different synthetic polymers having a broad range of mechanical, chemical, and biodegradable properties are obtained; the differences in properties and characteristics are controlled by varying the parameters of reaction temperatures, reactant concentration, types of solvent, and reaction time.

The poly(phosphate esters) and poly(phosphonate esters) of the invention can range in molecular weight from 2,000 to  $10^6$  containing from 10 to 10,000 monomeric units.

All of the compositions useful as prostheses or implants are synthetic poly(phosphate ester) and/or poly(phosphonate esters) compositions which share such characteristics as predictable and controllable degradation rates, biocompatibility and biodegradability, mechanical strength, and ease of fabrication.

The rate of biodegradation of the poly(phosphate ester) and poly(phosphonate esters) compositions of the invention may also be controlled by varying the hydrophobicity of the polymer. The mechanism of predictable degradation preferably relies on either group R' in the poly(phosphate ester) or poly-phosphonate esters) backbone being hydrophobic for example, an aromatic structure, or, alternatively, if the group R' is not hydrophobic, for example an aliphatic group, then the group R is preferably aromatic.

The rates of degradation for each poly(phosphate ester) and poly(phosphonate ester) composition are generally predictable and constant at a single pH. This permits the compositions to be introduced into the individual at a variety of tissue sites. This is especially valuable in that a wide variety of compositions and devices to meet different, but specific, applications may be composed and configured to meet specific demands, dimensions, and shapes - each of which offers individual, but different, predictable periods for degradation.

When the composition of the invention is used for long term delivery of a therapeutic agent a relatively hydrophobic backbone matrix, for example, containing bisphenol A, is preferred. It is possible to enhance the degradation rate of the poly(phosphate ester) or poly(phosphonate ester), or shorten the functional life of the device, by introducing hydrophilic or polar groups, into the backbone matrix. Further, the introduction of methylene groups into the backbone matrix will usually increases the flexibility of the backbone and decreases the crystallinity of the polymer. Conversely, to obtain a more rigid backbone matrix, for example, when used orthopedically, an aromatic structure, such as a diphenyl group, can be incorporated into the matrix. Also, the poly(phosphate esters) and poly(phosphonate esters) can be crosslinked, for example, using 1,3,5-trihydroxybenzene or  $(CH_2OH)_4C$ , to enhance the modulus of the polymer. Similar considerations hold for the structure of the side chain (R).

The entire class of poly(phosphate esters) and poly(phosphonate esters) are biocompatible and biodegradable. In view of their intended function as a therapeutic agent-bearing implant or prosthesis to be introduced into a subject *in vivo*, it is desirable that these compositions be essentially non-inflammatory, and non-immunogenic.

The use of the poly(phosphate esters) and poly(phosphonate esters) of the invention as an implant which also functions as a therapeutic agent-bearing polymeric composition, for example, subcutaneously or in various body cavities, is particularly useful in cases where chronic administration of drug over periods ranging from days to years is required. Examples of drugs which can be used in this manner include insulin for diabetes, pilocarpine for glaucoma, immune agents for various diseases and allergies, contraceptive steroids, narcotic antagonists, antibiotics, anticancer, and antihypertensive drugs.

Subcutaneous implantation is currently one of the most popular routes used for sustained drug delivery. This is partly due to the simplicity of the surgical procedures involved in implantation and removal, and the

relatively favorable absorption site offered compared to the oral or percutaneous routes. Surgery could be viewed as a disadvantage, however, depending on the patient and the location and frequency of implantation. It can be avoided in some cases by injecting the implant directly into subcutaneous tissue, provided the implant is capable of being delivered through a syringe. This is the method used for many of the sustained-release insulin products.

Implantation using a syringe is particularly effective when the composition of the invention is in the form of microspheres which can be suspended in a pharmaceutical buffer and introduced via the syringe to the desired site.

For example, compositions in the form of microspheres incorporating cortisone could be injected into the region of an inflammatory joint or muscle.

The use of the biodegradable polymers of the invention to act as a matrix for the release of a therapeutic agent from subcutaneously implanted compositions offers several advantages over prior art compositions. The most obvious is that no surgical removal of the device is necessary after it has fulfilled its function. Also, an additional mechanism for release of drug is provided by degradation. Complete delivery and, thus, maximal absorption occurs after the device has degraded.

The mechanism of release of therapeutic agent from biodegradable slabs, cylinders, and spheres has been described by Hopfenberg (in *Controlled Release Polymeric Formulations*, pp. 26-32, Paul, D.R. and Harris, F.W., Eds., American Chemical Society, Washington, D.C., 1976). A simple expression describing additive release from these devices where release is controlled primarily by matrix degradation is

$$M_t/M_\infty = 1 - [1 - k_0 t/C_0 a]^n$$

where  $n = 3$  for a sphere,  $n = 2$  for a cylinder, and  $n = 1$  for a slab. The symbol  $a$  represents the radius of a sphere or cylinder or the half-thickness of a slab.  $M_t$  and  $M_\infty$  are the masses of drug released at time  $t$  and at infinity, respectively.

Biodegradable subcutaneous implants can also be used, for example, for the delivery of narcotic antagonists, steroids, and anticancer agents. Narcotic antagonists, such as naltrexone, cyclazocine, and naloxone, are therapeutically useful in the postdetoxification stage of rehabilitation of drug-dependent patients. Steroids which can be used include contraceptives (for example, progesterone), anti-inflammatory agents (for example, dexamethasone), and anabolics (for example, estradiol). Anticancer agents which can be used include cyclophosphamide, doxorubicin, and cisplatin.

Intravaginal implants are used for the sustained release of contraceptive steroid hormones due to the more favorable site of absorption offered by the vaginal mucosa relative to the oral route for these drugs. First-pass hepatic metabolism, which inactivates many steroid hormones, and gastrointestinal incompatibility are avoided by using the vaginal route. In addition, the vaginal route allows self-insertion ensuring better patient compliance. More stable poly(phosphate esters) are preferred in this usage.

The intrauterine device (IUD) is one of the more popular methods of contraception which can utilize the compositions of the invention. Initial investigations involving nonmedicated IUDs revealed that the larger the device, the more effective it was in preventing pregnancy. Unfortunately, large devices caused increased incidences of uterine cramps, bleeding, and expulsion. The effort to improve intrauterine contraception and avoid previously demonstrated side effects has led to the development of medicated IUDs. More stable poly(phosphate ester) and poly(phosphonate esters) are preferred in this usage. Two classes of agents have been used in IUDs of this type: contraceptive metals, such as copper, and steroid hormones, such as progesterone.

The compositions of the invention are also useful in the treatment of glaucoma. Chronic open-angle glaucoma usually requires therapy for the lifetime of the patient with a miotic agent such as pilocarpine, for control of intraocular pressure. Conventional pilocarpine therapy requires instillation of eyedrops four times a day. Hence, compositions of the invention incorporating an anti-glaucoma agent such as pilocarpine would require less frequent and more sustained administration.

The above disclosure generally describes the present invention. A further understanding can be obtained by reference to the following specific examples which are provided herein for purposes of illustration only.

**EXAMPLE 1****GENERAL POLYMER SYNTHESIS TECHNIQUES**

5       Four different methods were used for the synthesis of the phosphorus-containing polymers: bulk polycondensation, solution polymerization, interfacial polycondensation, and ring-opening polymerization. In these syntheses, care was taken to eliminate traces of moisture from the system. The reaction vessels were carefully dried and purged with dry nitrogen before use. The nitrogen stream was passed through a Deoxo purifier for oxygen removal. The polymerization, except in the case of interfacial polycondensation, was  
 10      conducted under nitrogen sweep. All reactants were fractionally distilled under vacuum or recrystallized before use. In particular, the phosphorus diacid chlorides were freshly distilled before each experiment. Solvents were dried over molecular sieves. The phase transfer catalysts of cetyltrimethylammonium chloride and crown ether 18 were used for the interfacial polycondensation. Lewis acids of ferric chloride and magnesium chloride were used for melt-polycondensation. For ring-opening polymerization, t-BuOK or  
 15       $(i\text{-C}_4\text{H}_9)_3\text{Al}$  were used as initiators. In reactions involving diols oxidizable to quinones in base the procedures were performed in the dark, and small amounts of sodium hydrosulfite were added to the interfacial polycondensation to prevent oxidation of the diol.

**A. Melt-Polycondensation:**

20       In melt, or bulk, polycondensation the phosphonic or phosphoric dichloride is mixed with the diol in the absence of solvent. A Lewis acid catalyst ( $\text{FeCl}_3$ ,  $\text{MgCl}_2$ , etc.) is added and the mixture is heated, often under vacuum or nitrogen blanket, to remove the  $\text{HCl}$  formed. These somewhat vigorous conditions can lead to chain acidolysis (or hydrolysis if water is present). Unwanted, thermally induced side reactions such as  
 25      adventitious crosslinking can also occur if the polymer backbone is susceptible to hydrogen atom abstraction or oxidation with subsequent macroradical recombination. On the positive side, this technique avoids solvents and large amount of other additives, thus making purification more straightforward. It can also provide polymers of reasonable molecular weight.

**B. Solution-Polycondensation:**

30       Solution polycondensation requires that both the diol and the phosphorus component be soluble in a common solvent. Typically, a chlorinated organic solvent was used and the reaction run in the presence of a stoichiometric amount of an acid acceptor. The product was then isolated from the solution by  
 35      precipitation and purified to remove the hydrochloride salt. Although longer reaction times may be necessary, generally much milder conditions are used relative to bulk-reactions. More sensitive functionality can thus be incorporated using this technique.

**C. Interfacial-Polycondensation:**


40       Interfacial polycondensation potentially yields high molecular weights for these polymers at high reaction rates. Since the interfacial technique is a non-equilibrium method, the critical dependence of high molecular weight on exact stoichiometric equivalence between diol and dichloride inherent in bulk and solution methods is removed. The limitation of this method is the hydrolysis of the acid chloride in the  
 45      alkaline aqueous phase. Phosphoro-dichloridates which have some solubility in water are generally subject to hydrolysis rather than polymerization.

**D. Ring Opening:**

50       Ring-opening polymerization of phosphorus-containing monomers was performed using the technique disclosed in Lapienis, et al., *Journal of Polymer Science*, Part A: *Polymer Chemistry*, 25:1729, 1987 and Pretula, et al., *Macromolecules*, 19:1797, 1986. This technique is particularly useful in producing high molecular weight polymers.


**EXAMPLE 2****PREPARATION OF POLY(PHOSPHATE ESTERS) AND POLY(PHOSPHONATE ESTERS)**

- 5 A. Using the melt-condensation technique, a poly(phosphate ester) having the structure disclosed in  
Equation 6 was produced. Ethyl phosphorodichloridate was slowly added to a magnetically stirred  
mixture of an equimolar amount of ethylene glycol containing 2 mole percent of  $\text{FeCl}_3$  cooled to  $-20^\circ\text{C}$ .  
The flask was connected to a vacuum pump through a trap to remove HCl. When the addition was  
complete, the temperature was gradually raised to  $120^\circ\text{C}$  over a seven hour period. The mass was then  
10 cooled to room temperature, dissolved in methanol, and precipitated into ether.



- B. Using the solution-polycondensation technique, a poly(phosphate ester) with the structure disclosed in  
Equation 7 was produced.


A solution of recrystallized bisphenol-A (10.0 g, 43.8 mmol) and dried pyridine (7.62 g, 2.2 equiv.) in  
20 100 ml of dried methylene chloride was cooled to  $5^\circ\text{C}$  in a 500 ml three-necked flask equipped with a  
paddle stirrer, thermometer, and gas inlet and exit tubes. Under positive pressure of dry nitrogen, a  
solution of 7.14g (43.8 mmol) of freshly distilled ethyl phosphorodichloridate in 25 ml of methylene  
chloride was added from an addition funnel over a period of 30 minutes. An increase in viscosity was  
noted during the addition. When the addition was complete, the temperature was allowed to rise to  $25^\circ\text{C}$   
25 and stirring was continued under nitrogen for 18 hours. The precipitate of pyridine hydrochloride was  
removed by filtration and the filtrate was washed twice with 40 ml of distilled water. After drying over  
CaCl<sub>2</sub>, the methylene chloride solution was concentrated and precipitated into 500 ml of petroleum ether.  
The oily isolated was dried on a vacuum line at room temperature for 16 hours to give 8.42g (60.4%  
30 yield) of the poly(phosphate) as a crisp white foam having  $M_w = 17,000$  (by GPC relative to polystyrene  
in chloroform).



- C. The poly(phosphate ester) of Equation 8 was produced using the interfacial polycondensation  
40 technique.

A solution of recrystallized bisphenol-A (10.0g, 43.8 mmol) and sodium hydroxide (3.66g, 1.04 equiv.)  
in 65 ml of distilled water was prepared; 1.12g (2 mole percent) of a 25% aqueous solution of  
45 cetyltrimethylammonium chloride (CTMAC) was then added with stirring. Separately a solution of  
phenylphosphonodichloridate (8.59g, 43.8 mmol) in 60 ml of dried methylene chloride was prepared in a  
dropping funnel and kept under nitrogen. Both of these solutions were then cooled to  $0^\circ\text{C}$ . The aqueous  
solution was transferred to the jar of a 1 L Waring commercial blender; low speed mixing was begun  
immediately. The organic solution was run into the agitated solution from the funnel through a hole in the  
50 cap over a one-minute period. The mixture was blended for four minutes, producing a thick, milky  
emulsion with a temperature of  $35^\circ\text{C}$ . After separating the layers in a separatory funnel, the lower  
organic layer was washed with 30 ml of water, dried over CaCl<sub>2</sub>, and precipitated into 750 ml of  
petroleum ether to give a fibrous, powdery solid. The solid was isolated by filtration, reprecipitated in the  
same manner, isolated again, and dried on a vacuum line at room temperature for 16 hr to give the  
polyphosphonate (15.1 g, 98.4%) as a fine powder.

(Eq. 8)




10

D. The ring-opening technique was used to produce the poly(phosphate ester) shown in Equation 9. Using dioxaphosphorinane at a concentration of 7.0 mol/L in methylene chloride, a polymer with a number average molecular weight of over 100,000 was obtained as a white, powdery material in about 50% yield when triisobutylaluminum (0.03 M) was used as the initiator at 25 °C after a 24 hour reaction (Eq. 9). The difficulty of this technique is the preparation of the pure cyclic monomers. In order to maintain a favorable thermodynamic driving force for the ring-opening reaction, the monomer is confined to aliphatic and non-bulky groups. The cyclic monomer also should not contain acidic protons.

20

(Eq. 9)



25

Additional examples of some of the poly(phosphate esters) which have been synthesized using the above techniques and their properties are shown in Table 1.

30

35

40

45

50

55

Table 1

Polymer	R	R'	Method	Properties
5	I	-OC <sub>2</sub> H <sub>5</sub>	1	A dark brown solid, swells in hot water
		-OC <sub>2</sub> H <sub>5</sub>	1	C white powder; M <sub>n</sub> =3879, M <sub>w</sub> =35365, T <sub>m</sub> =60-70°C
		-OC <sub>2</sub> H <sub>5</sub>	1	B M <sub>n</sub> =3920
	II	-OC <sub>2</sub> H <sub>5</sub>	2	C T <sub>m</sub> =110-130°C; solution in chloroform
	III	-OC <sub>2</sub> H <sub>5</sub>	3	C [ ]=0.16 dL/g, soluble in DMF
10	IV	-OC <sub>2</sub> H <sub>5</sub>	4a	A waxy solid, T <sub>m</sub> =30-35°C, soluble in pH 7.4 phosphate buffer, slow decomposition in air (spongy)
	V	-OC <sub>2</sub> H <sub>5</sub>	4b	A solid swells up to 560% in 48 hours in pH 7.4 phosphate buffer, swells in MeOH and chloroform, T <sub>m</sub> =140-220°C
15	VI	-OC <sub>2</sub> H <sub>5</sub>	4c	A swells in buffer, T <sub>m</sub> =90°C
	VII	-OC <sub>2</sub> H <sub>5</sub>	4d	A water soluble, T <sub>m</sub> =55-65°C
	VIII	-C <sub>6</sub> H <sub>5</sub>	1	C M <sub>n</sub> =4917, M <sub>w</sub> =33867
	IX	-OC <sub>6</sub> H <sub>5</sub>	1	C M <sub>n</sub> =3745, M <sub>w</sub> =34860
20	X	-OC <sub>6</sub> H <sub>5</sub> (NO <sub>2</sub> )	1	C yellow sticky material



A = melt-condensation with MgCl<sub>2</sub> as catalyst

B = solution polymerization in refluxing methylene chloride

C = aqueous interfacial condensation (CH<sub>2</sub>Cl<sub>2</sub>-H<sub>2</sub>O) with phase transfer catalysts

25

30



35




4 = -(CH<sub>2</sub>CH<sub>2</sub>O-)<sub>m</sub>-  
for 4a, m = 14  
for 4b, m = 34  
for 4c, m = 77  
for 4d, m = 182

40

EXAMPLE 3COMPARATIVE RELEASE RATES OF COMPOUNDS FROM PENDANT AND MATRIX SYSTEMS

45 Poly (phosphate ester) and poly(phosphonate esters) compositions were prepared which contained benzoic acid, aniline, thiophenol, or p-nitrophenol in pendant position in combination with an aliphatic backbone, as shown in Equation 10.

50



55 R = benzoic acid, aniline, thiophenol, or p-nitrophenol

The ring-opening polymerization technique was used to prepare poly(2-chloro-2-oxo-1,3,2-dioxaphosphite). To prepare the cyclic monomer 2-hydro-2-oxo-1,3,2-dioxaphosphite, a solution (100 ml) of 1,3-propanediol (0.165 mole) and triethylamine (TEA) (0.33 mole) in benzene was added dropwise to vigorously stirred

anhydrous benzene (200 ml) at 0°C under nitrogen atmosphere. Phosphorus trichloride (0.165 mole) in anhydrous benzene (200 ml) was then added. After a reaction of two hours and the TEA HCl salt filtered off, a mixture of water (0.2 mole), TEA (0.2 mole), and tetrahydrofuran (10 ml) were added dropwise. After two hours of vigorous agitation, the solvent was removed under reduced pressure. The residue was separated by flash chromatography using silica as the packing material and chloroform/toluene (50:50) as the mobile phase. The purity of the monomer was checked by thin layer chromatography (TLC). The TLC plates were developed by iodine vapor for visualization.

The polymers were synthesized by anionic polymerization of 2-hydro-2-oxo-1,3,2-oxaphosphorinane. The anionic polymerization was conducted in methylene chloride at -15°C for 48 hours under nitrogen atmosphere. A 1 mole % of i-Bu<sub>3</sub>Al was used as the anionic initiator. The polymer was isolated by repeated precipitation into dried benzene. Chlorination of the polymer was achieved by passing dried chlorine through a solution of the polymer in methylene chloride until a persistent, yellow color was obtained (about three hours). The excess chlorine was then removed by vacuum at room temperature. The polymers were characterized by GPC, intrinsic viscosity, FT-IR, and FT-NMR.

After chlorination, the compounds were linked to the side chain of the polymer via dehydrochlorination. The chemical structures containing different R groups were all confirmed by FTIR and UV spectrophotometry. Figure 1a shows the *in vitro* release of the R groups from polymer.

The drug release rate was dependent on the stability of the linkage bond. For instance, benzoic acid was bound to the polymer via a phosphoric anhydride bond, which is extremely water labile. Consequently, a high release rate was seen. The model drugs are all water soluble compounds, which in a diffusion-controlled release system would be depleted very quickly.

Shown in Figure 1b is the comparison of the release of p-nitrophenol and aniline from a matrix system (in which the drug is just physically dispersed in the polymer and compression molded into a disc) and that released from the pendant system (in which the polymer-drug conjugates are compression molded to the same dimension). The time it took for 50% of the drug to be released from the polymer-drug conjugate was significantly longer, showing that the pendant system is indeed capable of prolonging the release of hydrophilic drugs through a phosphate ester or a phosphoroamide bond.

#### EXAMPLE 4

30


#### **COMPARISON OF DEGRADATION RATES OF VARIOUS BPA POLYMERS**

Various poly(phosphate esters) and poly(phosphonate esters) were prepared having a bisphenol A (BPA) backbone and their rates of *in vitro* degradation compared.

These polymers were prepared in a manner similar to that disclosed in Example 1 B or C except for the substitutions to the phosphochloridate. The four side chains of Table 2 were commercially available from Aldrich Chemicals.

In order to use side chains of other structures it is possible to start with the phosphorochloride of

40



where R is the desired structure. The monomer can be obtained either commercially or custom synthesized. Such synthesis can be carried out, for example, by reacting phosphorous oxychloride with the desired structure in the presence of an acid acceptor in an organic solvent, according to the general equation:

50




55

The polymers prepared had the structures indicated in Table 2.

Table 2

5


10



15

20

25

R $-\text{OC}_2\text{H}_5$  $-\text{C}_2\text{H}_5$ Designation**BPA-EOP****BPA-EP****BPA-POP****BPA-PP**

30 These polymers were then placed in pH 12 phosphate buffer and their relative rates of degradation determined.

35 The degradation experiments were conducted in 0.1M phosphate buffer (pH 12). The polymers were compression molded into discs (1 cm x 2 mm), placed in 50 ml of pH 12 buffer, and incubated at 37°C. The release kinetics were followed by measuring the concentrations of the buffer solution by HPLC. The weight loss of the discs as a function of time was also recorded.

The results are illustrated in Figure 2. As expected, the hydrolysis was base catalyzed. In pH 7.4 buffer at 37°C, BPA-EOP lost less than 5% of its weight in 10 days. In a 0.1 M NaOH solution at 37°C, the polymer completely decomposed in less than one week.

40 **EXAMPLE 5**

**COMPARISON OF NON-PENDANT DRUG RELEASE RATES FROM BPA POLYMERS**

45 Poly(phosphate esters) and poly(phosphonate esters) with a bisphenol A backbone and different side chains were prepared as described in Example 4 and compared in terms of their *in vitro* release of different drugs.

In a first experiment compositions of BPA-PP, BPA-POP, BPA-EP, and BPA-EOP incorporating cortisone or lidocaine were compared.

50 Drugs were incorporated into the matrix by compression molding. The polymer was ground and sieved into a particle size range below 90 microns. Drugs were sieved to the same particle size range and blended in a Vortex mixer with the polymer powder. The mixture was pressed into a disc (10 mm x 2 mm) through a mold, at a pressure of 150 Kpsi and room temperature for 10 min. Such a high molding pressure is useful in forming a compact matrix for desirable sustained release. The molds were specifically made with carbon and heat treated plungers to withstand the high pressure. The poly(phosphate ester)-drug and poly(phosphonate ester)-drug conjugates are similarly molded for implantation.

A solvent evaporation technique was used to prepare the microspheres. A solution of 2 g of polymer and 0.4 g of drug in 20 ml of methylene chloride was prepared. The mixture was emulsified in 150 ml of water containing 0.5 wt % of poly(vinyl alcohol) in a homogenizer. The methylene chloride in the emulsion

was evaporated over a period of one hour at room temperature at a reduced pressure of 40 mm Hg. The microspheres thus obtained were quickly washed with cold water and filtered. After drying, the microspheres were sieved to a narrow size fraction before use. This technique can be used to encapsulate, for example, such organic substances as sucrose and nerve growth factor.

5 Release experiments were conducted in a 0.1M pH 7.4 phosphate buffer containing 0.02 wt % of gentamicin sulfate to inhibit bacterial growth. The drug-loaded matrices were placed in 10 ml of buffer in 20 ml vials and incubated at 37°C. The release kinetics were followed by measuring the concentrations of the buffer solutions by scintillation counting and high pressure liquid chromatography (HPLC). HPLC analysis was used to determine the degradation rate of the matrix and to check the chemical purity of the drug. To  
 10 approximate perfect sink conditions, the frequency of replacement of the buffer solutions was adjusted during the course of the release study to ensure that the drug concentration in buffer was below 20% of its saturation value. In situations where the release rates are rapid (100 percent release in less than 2 days) and when dealing with microspheres, the experiment was conducted in a flow system. The matrices or the microspheres were placed in a glass vial equipped with a glass filter and Teflon stopcock in the bottom. A  
 15 counter-gravitational flow of 0.1 M pH 7.4 phosphate buffer was passed through the sample at a rate of 0.5 ml/min. Both the buffer reservoir and the release vessel were immersed in a 37°C bath. The eluent was collected every hour and subjected to chromatographic and spectrophotometric analyses.

The release kinetics are shown for cortisone in Figure 3. The data indicate that the release rate was dependent on the chemical structure of the side chain (R). This is the first study which demonstrates  
 20 systematically that the variation of the side chain of a biodegradable polymer can control the release rates. The EOP and EP side chains generally give faster release rates because they are less hydrophobic than the POP and PP structures. Noteworthy is the constant release of cortisone from the polymers.

In a second experiment, the release kinetics of various non-pendant drugs were measured for BPA-EOP derived matrix compositions. As shown in Figure 5, all four drugs were released in intact form from the  
 25 polymer as determined by HPLC. These release profiles show that, in general, drugs of higher water solubility have higher release rates.

#### **EXAMPLE 6**

#### **30 PREPARATION OF PENDANT 5-FLUOROURACIL COMPOSITIONS**


A mixture of 5-FU (7 mmole) and 1,1,1,3,3-hexamethyldisilazane (30 ml) were heated at reflux temperature for 20 hours in the presence of a catalytic amount of ammonium sulphate to derivatize 5-FU. Evaporation of the mixture under reduced pressure resulted in the formation of 2,4-bis-o-trimethylsilyl-5-  
 35 fluorouracil. To obtain the final polymer-drug conjugate, the chlorinated poly(phosphate ester) (5g) in methylene chloride (20 ml) was reacted with the 5-FU derivative in the presence of a stoichiometric amount of pyridine. After stirring for 18 hours at room temperature, 15 ml of methanol was added. After evaporation of the solvent, the residue was redissolved in dimethyl formamide and repeatedly precipitated into acetone. Linking of iodoaminopurine (IAP) to the polymer can be achieved in a similar manner by taking advantage  
 40 of the facile reaction between the primary amine of the drug and the chlorine in the side chain of the polymer.

In the *in vitro* release studies (as in Example 5), a sustained release of 5-FU was observed for at least 7 days and chemical integrity of the 5-FU was confirmed by HPLC. This release rate is far superior to similar studies with 5-FU pendently attached to a polyhydride carrier where nearly complete release  
 45 occurred after only 2 days.

#### **Claims**

**Claims for the following Contracting States : AT, BE, CH, DE, DK, FR, GB, GR, IT, LI, LU, NL, SE**


50 1. A polymer which comprises units represented by the formula:





wherein n ranges from 10 to 10<sup>5</sup>, R' is:

$-(CH_2)_a-$ ,  $-(CH_2CH_2O)_b-$ ,




5






10



15



20




wherein R<sub>1</sub> is independently alkyl, halogen, nitro, hydroxyl, amino, carboxyl, or alkoxy, R<sub>2</sub> is oxygen or N-CH<sub>3</sub> and a ranges from 2 to 6, b ranges from 10 to 100, d ranges from 2 to 16, f ranges from 1 to 6, and m ranges from 1 to 2 or R' is a therapeutic agent, and R is:

25


$-NH-R_1$ ,  $-S-R_1$ ,

30



$-OC_pH_{2p+1}$ ,  $-C_pH_{2p+1}$ ,

35



40

$-H$ ,  $-Cl$ ,  $-O-R_3$


wherein R<sub>1</sub> is independently alkyl, halogen, nitro, hydroxyl, amino, carboxyl, or alkoxy, R<sub>3</sub> is

45



or

50



55


and p ranges from 1 to 16 or R is a therapeutic agent.

2. The polymer of claim 1, wherein R is a first therapeutic agent and R' is a second therapeutic agent.

3. The polymer of claim 1, wherein said therapeutic agent is a drug, a radioisotope, a biological response modifier, a lectin, or a mixture thereof.
4. A therapeutic agent delivery vehicle containing a therapeutically effective amount of a therapeutic agent useful in achieving a medical effect, the vehicle comprising the polymer as in any one of claims 1 to 3.
5. A transient structural prosthesis comprising the polymer of claim 1.
6. A composition useful in providing transient structural prosthesis, the composition comprising the polymer of claim 1 wherein the composition further comprises a therapeutically effective amount of a therapeutic agent useful in achieving a medical effect not bound to the polymer.
- 10 7. Use of the polymer of any one of claims 1 to 3 for the preparation of a composition containing a therapeutically effective amount of a therapeutic agent which is useful in a method of achieving a medical effect.
- 15 8. Use according to claim 7, wherein said medical effect is chemotherapy, antibiotic therapy, birth control or metabolic regulation.
- 20 9. Use according to claim 7, wherein said therapeutic agent is a drug, a radioisotope, a biological response modifier, a lectin, or a mixture thereof.
10. Use of the polymer of claim 1 for the preparation of a transient structural prosthesis which is useful in a method of providing transient structural support to an individual.
- 25 11. Use according to claim 10, wherein said prosthesis is a bone plate, a suture or a clamp.

**Claims for the following Contracting State : ES**

- 30 1. A method for preparing a polymer which comprises units represented by the formula:




35



wherein n ranges from 10 to  $10^5$ , R' is:

$-(\text{CH}_2)_a-$ ,  $-(\text{CH}_2\text{CH}_2\text{O})_b-$ ,




40






45



50



55




**EP 0 386 757 B1**


wherein R<sub>1</sub> is independently alkyl, halogen, nitro, hydroxyl, amino, carboxyl, or alkoxy, R<sub>2</sub> is oxygen or N-CH<sub>3</sub> and a ranges from 2 to 6, b ranges from 10 to 100, d ranges from 2 to 16, f ranges from 1 to 6, and m ranges from 1 to 2, R' is a therapeutic agent, and R is:

—NH—R<sub>1</sub>, —S—R<sub>1</sub>,

5



10           —OC<sub>p</sub>H<sub>2p+1</sub>, —C<sub>p</sub>H<sub>2p+1</sub>,



15

—H, —Cl, —O—R<sub>3</sub>

wherein R<sub>1</sub> is independently alkyl, halogen, nitro, hydroxyl, amino, carboxyl, or alkoxy, R<sub>3</sub> is

20



or


25



30

and p ranges from 1 to 16 or R is a therapeutic agent which comprises reacting a compound of the formula

35



40

with a compound of the formula

HO-R'-OH

45

wherein R and R' are as defined above.

50


2. The method of claim 1, wherein R is a first therapeutic agent and R' is a second therapeutic agent.
3. The method of claim 1, wherein said therapeutic agent is a drug, a radioisotope, a biological response modifier, a lectin, or a mixture thereof.

55

**Patentansprüche****Patentansprüche für folgende Vertragsstaaten : AT, BE, CH, DE, DK, FR, GB, GR, IT, LI, LU, NL, SE**

1. Polymer, umfassend Einheiten der Formel:


5





10

in der n 10 bis  $10^5$  beträgt, R': $-(\text{CH}_2)_a-$ ,  $-(\text{CH}_2\text{CH}_2\text{O})_b-$ ,


15






20



25




30




35

ist, wobei R1 unabhängig ein Alkylrest, Halogenatom, eine Nitro-, Hydroxyl-, Aminogruppe, ein Carboxyl- oder Alkoxyrest ist, R2 ein Sauerstoffatom oder eine Gruppe N-CH3 ist und a 2 bis 6 beträgt, b 10 bis 100 beträgt, d 2 bis 16 beträgt, f 1 bis 6 beträgt und m 1 bis 2 beträgt oder R' ein therapeutischer Wirkstoff ist, und R:

40

 $-\text{NH}-\text{R}_1$ ,  $-\text{S}-\text{R}_1$ ,

45

 $-\text{OC}_p\text{H}_{2p+1}$ ,  $-\text{C}_p\text{H}_{2p+1}$ ,

50

 $-\text{H}$ ,  $-\text{Cl}$ ,  $-\text{O}-\text{R}_3$ 

ist, wobei R1 unabhängig ein Alkylrest, ein Halogenatom, eine Nitro-, Hydroxyl-, Aminogruppe, ein Carboxyl- oder Alkoxyrest ist,

R3



5

oder



10

15 ist, und p 1 bis 16 beträgt oder  $R$  ein therapeutischer Wirkstoff ist.

2. Polymer nach Anspruch 1, in dem  $R$  ein erster therapeutischer Wirkstoff ist und  $R'$  ein zweiter therapeutischer Wirkstoff ist.
- 20 3. Polymer nach Anspruch 1, in dem der therapeutische Wirkstoff ein Arzneistoff, ein Radioisotop, ein biologischer Reaktionsmodifikator, ein Lectin oder ein Gemisch davon ist.
- 25 4. Ein einen therapeutischen Wirkstoff abgebender Träger, der eine therapeutisch wirksame Menge eines therapeutischen Wirkstoffes enthält, der zum Erreichen einer medizinischen Wirkung geeignet ist, wobei der Träger das Polymer nach einem der Ansprüche 1 bis 3 umfaßt.
5. Übergangs-Strukturprothese, umfassend das Polymer nach Anspruch 1.
- 30 6. Zusammensetzung, die zur Bereitstellung einer Übergangs-Strukturprothese geeignet ist, wobei die Zusammensetzung das Polymer nach Anspruch 1 umfaßt, wobei die Zusammensetzung weiter eine therapeutisch wirksame Menge eines therapeutischen Wirkstoffs umfaßt, das zum Erreichen einer nicht an das Polymer gebundenen medizinischen Wirkung geeignet ist.
- 35 7. Verwendung des Polymers nach einem der Ansprüche 1 bis 3 zur Herstellung einer Zusammensetzung, die eine therapeutisch wirksame Menge eines therapeutischen Wirkstoffs enthält, das bei einem Verfahren zur Erreichung einer medizinischen Wirkung nützlich ist.
8. Verwendung nach Anspruch 7, wobei die medizinische Wirkung eine Chemotherapie, antibiotische Therapie, Geburtenkontrolle oder Stoffwechselregulierung ist.
- 40 9. Verwendung nach Anspruch 7, wobei der therapeutische Wirkstoff ein Arzneistoff, ein Radioisotop, ein biologischer Reaktionsmodifikator, ein Lectin oder ein Gemisch davon ist.
- 45 10. Verwendung des Polymers nach Anspruch 1 zur Herstellung einer Übergangs-Strukturprothese, die bei einem Verfahren der Bereitstellung einer Übergangs-Strukturunterstützung bei einer Person geeignet ist.
11. Verwendung nach Anspruch 10, wobei die Prothese eine Knochenplatte, eine Naht oder eine Klammer ist.


50

55

**Patentansprüche für folgenden Vertragsstaat : ES**

1. Verfahren zur Herstellung eines Polymers, umfassend Einheiten der Formel:


5





10

wobei n 10 bis  $10^5$  beträgt, R':  
 $-\text{CH}_2)_a-$ ,  $-(\text{CH}_2\text{CH}_2\text{O})_b-$ ,




15






20



25



30




35

ist, wobei R1 unabhängig ein Alkylrest, Halogenatom, eine Nitro-, Hydroxyl-, Aminogruppe, ein Carboxyl- oder Alkoxyrest ist, R2 ein Sauerstoffatom oder eine Gruppe N-CH3 ist und a 2 bis 6 beträgt, b 10 bis 100 beträgt, d 2 bis 16 beträgt, f 1 bis 6 beträgt und m 1 bis 2 beträgt, oder R' ein therapeutischer Wirkstoff ist, und R:


$-\text{NH}-\text{R}_1$ ,  $-\text{S}-\text{R}_1$ ,

40



45

$-\text{OC}_p\text{H}_{2p+1}$ ,  $-\text{C}_p\text{H}_{2p+1}$ ,



50

$-\text{H}$ ,  $-\text{Cl}$ ,  $-\text{O}-\text{R}_3$

ist, wobei R1 unabhängig ein Alkylrest, ein Halogenatom, eine Nitro-, Hydroxyl-, Aminogruppe, ein Carboxyl- oder Alkoxyrest ist,

55

R3



5


oder

10



ist, und p 1 bis 16 beträgt oder R ein therapeutischer Wirkstoff ist, umfassend die Umsetzung einer  
15 Verbindung der Formel

20



mit einer Verbindung der Formel

25

HO-R'-OH

in der R und R' die vorstehend angegebene Bedeutung haben.

- 30 2. Verfahren nach Anspruch 1, wobei R ein erster therapeutischer Wirkstoff ist und R' ein zweiter therapeutischer Wirkstoff ist.  
 3. Verfahren nach Anspruch 1, wobei der therapeutische Wirkstoff ein Arzneistoff, ein Radioisotop, ein biologischer Reaktionsmodifikator, ein Lectin oder ein Gemisch davon ist.


35

**Revendications**

**Revendications pour les Etats contractants suivants : AT, BE, CH, DE, DK, FR, GB, GR, IT, LI, LU, NL, SE**




- 40 1. Polymère qui comprend les motifs représentés par la formule :

45

dans laquelle n se situe dans la plage de 10 à 10<sup>5</sup>, R' est:-(CH<sub>2</sub>)<sub>a</sub>- , -(CH<sub>2</sub>CH<sub>2</sub>O)<sub>b</sub>- ,


50

55




20 dans laquelle R<sub>1</sub> est indépendamment alkyle, halogène, nitro, hydroxyle, amino, carboxyle, ou alcoxy, R<sub>2</sub> est oxygène ou N-CH<sub>3</sub> et a se situe dans la plage de 2 à 6, b dans la plage de 10 à 100, d dans la plage de 2 à 16, f dans la plage de 1 à 6, et m dans la plage de 1 à 2 ou R' est un agent thérapeutique et R est :

25 -NH-R<sub>1</sub>, -S-R<sub>1</sub>,



-OC<sub>p</sub>H<sub>2p+1</sub>, -C<sub>p</sub>H<sub>2p+1</sub>,



-H, -Cl, -O-R<sub>3</sub>

40 dans laquelle R<sub>1</sub> est indépendamment alkyle, halogène, nitro, hydroxyle, amino, carboxyle, ou alcoxy, R<sub>3</sub> est



ou



55 et p se situe dans la plage de 1 à 16 ou R est un agent thérapeutique.


2. Polymère selon la revendication 1, dans lequel R est un premier agent thérapeutique et R' est un second agent thérapeutique.

3. Polymère selon la revendication 1, dans lequel l'agent thérapeutique est un médicament, un radioisotope, un modificateur de la réponse biologique, une lectine ou un mélange de ceux-ci.
4. Véhicule d'administration d'agent thérapeutique contenant une quantité thérapeutiquement efficace d'un agent thérapeutique utile pour obtenir un effet médical, le véhicule comprenant le polymère selon l'une quelconque des revendications 1 à 3.
5. Prothèse structurelle provisoire comprenant le polymère de la revendication 1.
10. 6. Composition utile pour assurer une prothèse structurelle provisoire, la composition comprenant le polymère de la revendication 1, dans lequel la composition comprend, de plus, une quantité thérapeutiquement efficace d'un agent thérapeutique utile pour obtenir un effet médical non lié au polymère.
15. 7. Utilisation du polymère selon l'une quelconque des revendications 1 à 3, pour la préparation d'une composition contenant une quantité thérapeutiquement efficace d'un agent thérapeutique que est utile dans un procédé pour obtenir un effet médical.
20. 8. Utilisation selon la revendication 7, dans laquelle l'effet médical concerne la chimiothérapie, une thérapeutique antibiotique, la régulation des naissances ou la régulation du métabolisme.
25. 9. Utilisation selon la revendication 7, dans laquelle l'agent thérapeutique est un médicament, un radioisotope, un modificateur de la réponse biologique, une lectine ou leur mélange.
10. 10. Utilisation du polymère selon la revendication 1, pour la préparation d'une prothèse structurelle provisoire qui est utile dans un procédé pour fournir un support structurel provisoire à un patient.
11. Utilisation selon la revendication 10, dans laquelle la prothèse est une plaque osseuse, une suture ou une agrafe.

30. **Revendications pour l'Etat contractant suivant : ES**

1. Un procédé pour la préparation d'un polymère qui comprend les motifs représentés par la formule :

35






40

dans laquelle n se situe dans la plage de 10 à  $10^5$ , R' est:  
 $-(\text{CH}_2)_a-$  ,  $-(\text{CH}_2\text{CH}_2\text{O})_b-$  ,

45

50

55




dans laquelle R<sub>1</sub> est indépendamment alkyle, halogène, nitro, hydroxyle, amino, carboxyle, ou alcoxy,  
R<sub>2</sub> est oxygène ou N-CH<sub>3</sub> et a se situe dans la plage de 2 à 6, b dans la plage de 10 à 100, d dans la  
plage de 2 à 16, f dans la plage de 1 à 6, et m dans la plage de 1 à 2 ou R' est un agent  
thérapeutique et R est :

25      -NH-R<sub>1</sub>, -S-R<sub>1</sub>,



35      -OC<sub>p</sub>H<sub>2p+1</sub>, -C<sub>p</sub>H<sub>2p+1</sub>,



45      -H, -Cl, -O-R<sub>3</sub>

dans laquelle R<sub>1</sub> est indépendamment alkyle, halogène, nitro, hydroxyle, amino, carboxyle, ou alcoxy,  
R<sub>3</sub> est



ou



et p se situe dans la plage de 1 à 16 ou R est un agent thérapeutique qui comprend la mise en réaction d'un composé de la formule :

O .  
C1-P-C1  
R

5

avec un composé de la formule

HO-R'-OH

10

dans laquelle R et R' sont tels que définis ci-dessus.

2. Le procédé selon la revendication 1, dans lequel R est un premier agent thérapeutique et R' est un second agent thérapeutique.
- 15 3. Le procédé selon la revendication 1, dans lequel l'agent thérapeutique est un médicament, un radioisotope, un modificateur de la réponse biologique, une lectine ou leur mélange.

20

25

30

35

40

45

50

55

IN VITRO RELEASE OF MODEL COMPOUNDS FROM  
POLY(2-OXO-1, 3, 2-DIOXAPHOSPHITE)




FIG. 1a




FIG. 1b




FIG. 2


IN VITRO RELEASE OF CORTISONE FROM  
POLY(PHOSPHATE ESTERS) (10 WT% LOADING)

FIG. 3




FIG. 4